Results 111 to 120 of about 626,377 (227)

Inhibiteurs de PCSK9 : futur traitement pour baisser le cholestérol?

, 2014
The achievement rate of recommended low-density lipoprotein cholesterol (LDL-C) targets of < 1.8 mmol/l for secondary prevention in very high risk patients is difficult.
Mach, F, Rodondi, Nicolas, Gencer, B
core  

Leptin–cholesterol crosstalk in pregnancy: Mechanistic implications for placental function and cardiometabolic programming

Experimental Physiology, EarlyView.
Abstract Pregnancy requires the coordinated maternal reorganization of lipid and endocrine pathways to sustain fetal growth and anticipate neonatal nutrition. Leptin, produced by adipose tissue and the placenta, acts as an integrative signal linking maternal energy status with trophoblast function and vascular adaptation, while cholesterol provides ...
Julio Flores, Diego Gumera, Andreina Arias, Cristián A. Amador, María José Yañez   +4 more
wiley   +1 more source

PCSK9 inhibitors: a patent review 2018-2023 [PDF]

Introduction Proprotein convertase subtilisin/kexin 9 (PCSK9) plays a crucial role in breaking down the hepatic low-density lipoprotein receptor (LDLR), thereby influencing the levels of circulating low-density lipoprotein cholesterol (LDL-C ...
Citarella, Andrea, Albani, Marco, Lammi, Carmen, Legnani, Laura, Silvani, Alessandra, Fassi, Enrico Mario Alessandro, Milano, Erica Ginevra, Grazioso, Giovanni   +7 more
core   +1 more source

Therapeutic Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Althea Medical Journal
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a novel class of medications for managing dyslipidemia. Although previous meta-analyses have confirmed their efficacy in lowering low-density lipoprotein cholesterol ...
Nur Hafidha Hikmayani, Ratih Puspita Febrinasari, Ariq Ratya Satwika   +2 more
doaj   +1 more source

Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization

PLoS ONE, 2022
Prescription of PCSK9-inhibitors has increased in recent years but not much is known about its off-target effects. PCSK9-expression is evident in non-hepatic tissues, notably the brain, and genetic variation in the PCSK9 locus has recently been shown to ...
Alisha Aman, Eric A. W. Slob, Joey Ward, Breda Cullen, Nicholas Graham, Donald M. Lyall, Naveed Sattar, Rona J. Strawbridge   +7 more
doaj  

TNFSF14/LIGHT responses in intestinal and oesophageal fibroblasts are differentially modulated by hydroxylase inhibitors

The Journal of Physiology, EarlyView.
Abstract figure legend LIGHT is a mutual mediator of intestinal and oesophageal fibroblast inflammation with common as well as tissue‐specific effects. Hydroxylase inhibitors can selectively suppress inflammatory factors in both cell types, albeit targeting different signalling pathways.
Cian M. Ohlendieck, Carlos Matellan, Cristina Bauset, Bella Raphael, Mary Nwaezeigwe, Emer Flynn, Kevin Okamoto, Desmond Winter, Colm Collins, Katie Doogan, Seán T. Martin, Glen Doherty, Seema S. Aceves, Mario C. Manresa   +13 more
wiley   +1 more source

Efficacy and Safety of Oral Non‐Statin Lipid‐Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
A network meta‐analysis of 43 randomized trials showed that oral combination therapies, particularly obicetrapib plus ezetimibe and bempedoic acid plus ezetimibe, achieved the greatest LDL‐C reduction with reassuring safety profiles, supporting their use as effective oral alternatives for patients with dyslipidaemia. ABSTRACT Introduction Dyslipidaemia
Tamer Hodrob, Reem J. Saad, Aya Hamdy, Mariam Saleh Alheneedy, Ahmed Mohamed Shehata Abdelfattah Elsayed, Elsaghir Ghazy, Hazem Ayesh   +6 more
wiley   +1 more source

PCSK9 inhibition: from effectiveness to cost-effectiveness

Frontiers in Cardiovascular Medicine
Dyslipidaemia is a complex disorder characterised by abnormal lipid levels in the blood, including cholesterol and triglycerides, and plays an important role in the development of atherosclerotic cardiovascular disease.
Iveta Mercep, Iveta Mercep, Dominik Strikic, Pero Hrabac, Ivan Pecin, Željko Reiner, Željko Reiner   +6 more
doaj   +1 more source

Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?

Journal of Internal Medicine, Volume 300, Issue 5, Page 572-589, November 2026.
Abstract Hypocholesterolemia is perceived as benign given its association with lower cardiovascular risk. However, genetic and epidemiological evidence indicates that persistently low levels of low‐density lipoprotein cholesterol (LDL‐C) and apolipoprotein B (ApoB) arise from distinct biological mechanisms with different hepatic implications ...
Valentina Flagiello, Emelie Barreby, Umberto Vespasiani‐Gentilucci, Stefano Romeo   +3 more
wiley   +1 more source

PCSK9 Inhibitors

Journal of the American College of Cardiology, 2017
Mark A. Hlatky, Dhruv S. Kazi
openaire   +2 more sources